Investor Backing & Capital Strength:
Recent Series C and a $50M Series D tied to CT‑155, alongside strategic investment from Medidata/Dassault, indicate strong external support and added runway. Blue‑chip partners attaching capital to commercialization plans reinforce confidence in near‑term execution.
Product Line Growth:
FDA clearance and U.S. launch of Rejoyn, FDA authorization for CT‑132, and Phase 3 success for CT‑155 advance the portfolio from development to marketed or near‑market assets. Acquired assets like AspyreRx and the Click SE initiative further broaden offerings.
Strategic Partnerships:
Long‑standing collaborations with Otsuka, Boehringer Ingelheim, and Dassault Systèmes/Medidata underpin development, data capabilities, and commercialization pathways. These alliances suggest access to scale and expertise beyond a single company’s resources.
